Hopped Up

Dietmar Hopp is retaining his position as one of Germany's most active financial supporters of European biotech. Last week, vaccine company CureVac GmbH announced that dievini Hopp BioTech holding GmbH & Co. KG., its major shareholder with an 80% stake, was investing a further E27.6 million ($35.3 million).

Some of the money will support ongoing clinical trials of the company's therapeutic vaccines: CV9103, which is in Phase IIa for prostate cancer, and CV9201, which is in Phase I/IIa for non-small cell lung cancer. Data for the former are expected this year, while results from the latter are expected by the end of next year...